A Phase I/II Study of CR011-vcMMAE in Subjects With Unresectable Stage III or Stage IV Melanoma
This study has been completed.
Information provided by (Responsible Party):
Celldex Therapeutics ( CuraGen Corporation )
First received: December 18, 2006
Last updated: February 2, 2015
Last verified: February 2015
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||May 2011|
|Primary Completion Date:||December 2010 (Final data collection date for primary outcome measure)|
|Certification or Request for Extension to Delay Results Received:||February 2, 2015|
Ott PA, Hamid O, Pavlick AC, Kluger H, Kim KB, Boasberg PD, Simantov R, Crowley E, Green JA, Hawthorne T, Davis TA, Sznol M, Hwu P. Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma. J Clin Oncol. 2014 Nov 10;32(32):3659-66. doi: 10.1200/JCO.2013.54.8115.